他克他单抗是一种新批准的双特异性抗体，靶向 T 细胞上的 CD3 受体和在多发性骨髓瘤 (MM) 细胞上高表达的 G 蛋白偶联受体家族 C 组 5 成员 D (GPRC5D)。除了与双特异性抗体疗法相关的免疫治疗相关不良事件 (AE) 外，他克他单抗还与独特的皮肤/指甲和口腔 GPRC5D 相关副作用相关，需要额外的支持护理。本综述根据 MonumenTAL-1 (NCT03399799/NCT04634552) 临床试验期间肿瘤科护士的经验提供了他克他单抗的临床管理策略。本次综述的目的是提高护士和患者的认识，以更好地了解和管理与他克他单抗治疗相关的副作用，从而优化患者的治疗结果。MonumenTAL-1 是他克他单抗在复发/复发患者中进行的 1/2 期临床试验。难治的MM们，都是三级暴露。有关总体反应、安全性以及 AE 发生率和发生率的详细信息先前已发表。 T 细胞相关和独特 GPRC5D 相关 AE 的管理策略是从不同研究中心的肿瘤科护士那里收集的。在 MonumenTAL-1 研究中，他克他单抗显示复发/难治性 MM 患者的总体缓解率 > 71%。 AE 级别低且可预测；很少有导致研究终止的情况。肿瘤科护士基于参与 MonumenTAL-1 试验，拥有治疗管理监测方面的专业知识。这篇综述为学术和社区环境中的护士提供了如何监测、咨询和支持患者的信息，从而提高患者的生活质量和总体生存率。版权所有 © 2024 作者。由爱思唯尔公司出版。保留所有权利。

Talquetamab is a newly approved bispecific antibody targeting the CD3 receptor on T cells and a receptor, G protein-coupled receptor family C group 5 member D (GPRC5D), highly expressed on multiple myeloma (MM) cells. In addition to immune therapy-related adverse events (AEs) associated with bispecific antibody therapies, talquetamab is associated with unique skin/nail and oral GPRC5D-related side effects that require additional supportive care. This review provides clinical management strategies for talquetamab based on oncology nurses' experience during the MonumenTAL-1 (NCT03399799/NCT04634552) clinical trial. The objective of this review is to raise awareness among nurses and patients to better understand and manage the side effects associated with talquetamab treatment in order to optimize patient outcomes.MonumenTAL-1 is a phase 1/2 clinical trial of talquetamab in patients with relapsed/refractory MM who are triple-class exposed. Details on overall response, safety, and AE incidence and occurrence were previously published. Management strategies for the T-cell-related and unique GPRC5D-related AEs were collected from oncology nurses from different study sites.Talquetamab has shown overall response rates of >71% in patients with relapsed/refractory MM in the MonumenTAL-1 study. AEs were low grade and predictable; few led to study discontinuation.Oncology nurses have specialized knowledge of treatment administration monitoring based on their participation in the MonumenTAL-1 trial. This review provides information for nurses in both the academic and community settings on how to monitor, counsel, and support patients, which will in turn improve patients' quality of life and overall survival.Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.